Linda Oseso1, Amalia S Magaret, Keith R Jerome, Julie Fox, Anna Wald. 1. From the *Department of Epidemiology, †Department of Laboratory Medicine, ‡Department of Biostatistics, University of Washington; §Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and ¶Guy's and St Thomas' Hospital, London, United Kingdom; and ∥Department of Medicine, University of Washington, Seattle, WA.
Abstract
BACKGROUND: Current treatment of genital herpes is focused on ameliorating signs and symptoms but is not curative. However, as potential herpes simplex virus (HSV) cure approaches are tested in the laboratory, we aimed to assess the interest in such studies by persons with genital herpes and the willingness to assume risks associated with experimental therapy. METHODS: We constructed an anonymous online questionnaire that was posted on websites that provide information regarding genital herpes. The questions collected demographic and clinical information on adults who self-reported as having genital herpes, and assessed attitudes toward and willingness to participate in HSV cure clinical research. RESULTS: Seven hundred eleven participants provided sufficient responses to be included in the analysis. Sixty-six percent were women; the median age was 37 years, and the median time since genital HSV diagnosis was 4.7 years. The willingness to participate in trials increased from 59.0% in phase 1 to 68.5% in phase 2, and 81.2% in phase 3 trials, and 40% reported willingness to participate even in the absence of immediate, personal benefits. The most desirable outcome was the elimination of risk for transmission to sex partner or neonate. The mean perceived severity of receiving a diagnosis of genital HSV-2 was 4.2 on a scale of 1 to 5. CONCLUSIONS: Despite suppressive therapy available, persons with genital herpes are interested in participating in clinical research aimed at curing HSV, especially in more advanced stages of development.
BACKGROUND: Current treatment of genital herpes is focused on ameliorating signs and symptoms but is not curative. However, as potential herpes simplex virus (HSV) cure approaches are tested in the laboratory, we aimed to assess the interest in such studies by persons with genital herpes and the willingness to assume risks associated with experimental therapy. METHODS: We constructed an anonymous online questionnaire that was posted on websites that provide information regarding genital herpes. The questions collected demographic and clinical information on adults who self-reported as having genital herpes, and assessed attitudes toward and willingness to participate in HSV cure clinical research. RESULTS: Seven hundred eleven participants provided sufficient responses to be included in the analysis. Sixty-six percent were women; the median age was 37 years, and the median time since genital HSV diagnosis was 4.7 years. The willingness to participate in trials increased from 59.0% in phase 1 to 68.5% in phase 2, and 81.2% in phase 3 trials, and 40% reported willingness to participate even in the absence of immediate, personal benefits. The most desirable outcome was the elimination of risk for transmission to sex partner or neonate. The mean perceived severity of receiving a diagnosis of genital HSV-2 was 4.2 on a scale of 1 to 5. CONCLUSIONS: Despite suppressive therapy available, persons with genital herpes are interested in participating in clinical research aimed at curing HSV, especially in more advanced stages of development.
Authors: Maria A Nagel; April Rempel; Jonathon Huntington; Forrest Kim; Alexander Choe; Don Gilden Journal: J Virol Date: 2014-04-30 Impact factor: 5.103
Authors: H M Elbadawy; M Gailledrat; C Desseaux; G Salvalaio; E Di Iorio; B Ferrari; M Bertolin; V Barbaro; M Parekh; R Gayon; D Munegato; E Franchin; A Calistri; G Palù; C Parolin; D Ponzin; S Ferrari Journal: Gene Ther Date: 2014-01-16 Impact factor: 5.250
Authors: Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel Journal: N Engl J Med Date: 2009-02-12 Impact factor: 91.245
Authors: Karen E Mark; Spotswood Spruance; George R Kinghorn; Stephen L Sacks; Herbert B Slade; Tze-Chiang Meng; Stacy Selke; Amalia Magaret; Anna Wald Journal: Antimicrob Agents Chemother Date: 2014-04-07 Impact factor: 5.191